BR112017000389A2 - sistema de expressão cistrônico duplo e processo de produção de proteínas - Google Patents

sistema de expressão cistrônico duplo e processo de produção de proteínas

Info

Publication number
BR112017000389A2
BR112017000389A2 BR112017000389A BR112017000389A BR112017000389A2 BR 112017000389 A2 BR112017000389 A2 BR 112017000389A2 BR 112017000389 A BR112017000389 A BR 112017000389A BR 112017000389 A BR112017000389 A BR 112017000389A BR 112017000389 A2 BR112017000389 A2 BR 112017000389A2
Authority
BR
Brazil
Prior art keywords
expression system
production process
protein production
cistronic expression
dual cistronic
Prior art date
Application number
BR112017000389A
Other languages
English (en)
Inventor
Varshney Brajesh
Salunkhe Shardul
SOORAPANENI Sudheerbabu
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of BR112017000389A2 publication Critical patent/BR112017000389A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
    • A01H6/00—Angiosperms, i.e. flowering plants, characterised by their botanic taxonomy
    • A01H6/34—Cucurbitaceae, e.g. bitter melon, cucumber or watermelon 
    • A01H6/342—Citrullus lanatus [watermelon]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/27—Erwinia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24029—Aureolysin (3.4.24.29)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Physiology (AREA)
  • Botany (AREA)
  • Developmental Biology & Embryology (AREA)
  • Environmental Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

a presente invenção refere-se ao sistema de expressão cistrônico independente duplo em um único vetor para a produção de proteínas e peptídeos de interesse expressos na forma de corpos de inclusão insolúveis formados na bactéria e. coli. a presente invenção também fornece o processo de expressão da proteína de interesse utilizando o mencionado vetor bacteriostático.
BR112017000389A 2014-07-09 2015-07-09 sistema de expressão cistrônico duplo e processo de produção de proteínas BR112017000389A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2245MU2014 2014-07-09
PCT/IB2015/055189 WO2016005931A1 (en) 2014-07-09 2015-07-09 Dual cistronic bacterial expression system

Publications (1)

Publication Number Publication Date
BR112017000389A2 true BR112017000389A2 (pt) 2018-01-23

Family

ID=53773474

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017000389A BR112017000389A2 (pt) 2014-07-09 2015-07-09 sistema de expressão cistrônico duplo e processo de produção de proteínas

Country Status (20)

Country Link
US (2) US10329571B2 (pt)
EP (1) EP3167065B1 (pt)
JP (1) JP6748061B2 (pt)
CN (1) CN106661588B (pt)
AU (1) AU2015287296A1 (pt)
BR (1) BR112017000389A2 (pt)
CA (1) CA2954594A1 (pt)
CY (1) CY1123303T1 (pt)
DK (1) DK3167065T3 (pt)
ES (1) ES2808906T3 (pt)
HR (1) HRP20200996T1 (pt)
HU (1) HUE050300T2 (pt)
LT (1) LT3167065T (pt)
MX (1) MX2017000332A (pt)
PH (1) PH12017500047A1 (pt)
PL (1) PL3167065T3 (pt)
PT (1) PT3167065T (pt)
RU (1) RU2732148C2 (pt)
SI (1) SI3167065T1 (pt)
WO (1) WO2016005931A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6435770B2 (ja) * 2014-01-21 2018-12-12 東ソー株式会社 シグナルペプチドをコードするポリヌクレオチドおよびそれを用いたタンパク質の製造方法
WO2017021819A1 (en) * 2015-07-31 2017-02-09 Dr. Reddy’S Laboratories Limited Process for preparation of protein or peptide
MX2019013750A (es) 2017-05-19 2020-07-20 Council Scient Ind Res Un metodo para producir ranibizumab humanizado recombinante replegado.
US11851666B2 (en) 2017-08-23 2023-12-26 Novartis Ag Multi-copy gene protein expression system
JP7185006B2 (ja) * 2018-07-06 2022-12-06 ワッカー ケミー アクチエンゲゼルシャフト 発酵法で組換えタンパク質を放出する細菌株
JP2020120622A (ja) * 2019-01-31 2020-08-13 Ｓｐｉｂｅｒ株式会社 組換え細胞、発現構築物、及び組換えタンパク質の製造方法
WO2020202208A1 (en) * 2019-04-02 2020-10-08 Council Of Scientific & Industrial Research Cloning and expression of in-vivo refolded antibody fragment
CN114774453B (zh) * 2022-03-14 2023-04-21 湖北大学 一种运动发酵单胞菌基因表达严谨调控系统的构建方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3951062B2 (ja) 1991-09-19 2007-08-01 ジェネンテック・インコーポレーテッド 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用
ES2312494T3 (es) 2000-12-14 2009-03-01 Genentech, Inc. Produccion de anticuerpos completos en celulas procariotas.
CA2454731C (en) * 2001-08-27 2010-11-02 Genentech, Inc. A system for antibody expression and assembly
JP2009542232A (ja) * 2006-07-10 2009-12-03 エスバテック・アーゲー 上皮および／または内皮層を通過するｓｃＦｖ抗体
RU2413769C1 (ru) * 2009-12-24 2011-03-10 Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pET-32a, КОДИРУЮЩАЯ ГЕН ЛИГАНД-СВЯЗЫВАЮЩЕГО ДОМЕНА РЕЦЕПТОРА II ТИПА ТРАНСФОРМИРУЮЩЕГО ФАКТОРА РОСТА-β ЧЕЛОВЕКА (TβRII), ШТАММ БАКТЕРИЙ Escherichia coli - ПРОДУЦЕНТ СЛИТНОГО БЕЛКА ТИОРЕДОКСИН/TβRII И СПОСОБ РЕНАТУРАЦИИ И ОЧИСТКИ ЦЕЛЕВОГО БЕЛКА TβRII
GB201002730D0 (en) * 2010-02-18 2010-04-07 Uni I Oslo Product
WO2011151714A1 (en) 2010-06-04 2011-12-08 Lupin Limited Modified sak gene for the production of recombinant proteins
MY186731A (en) * 2013-03-08 2021-08-14 Neuclone Biologics Pty Ltd A cell expression system
US9914770B2 (en) * 2013-04-30 2018-03-13 Intas Pharmaceuticals Ltd Cloning, expression and purification method for the preparation of ranibizumab
TW201534726A (zh) * 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途

Also Published As

Publication number Publication date
LT3167065T (lt) 2020-07-27
HUE050300T2 (hu) 2020-11-30
US11365418B2 (en) 2022-06-21
EP3167065B1 (en) 2020-03-25
AU2015287296A1 (en) 2017-02-02
DK3167065T3 (da) 2020-07-06
JP6748061B2 (ja) 2020-08-26
CY1123303T1 (el) 2021-12-31
CA2954594A1 (en) 2016-01-14
CN106661588A (zh) 2017-05-10
RU2732148C2 (ru) 2020-09-11
EP3167065A1 (en) 2017-05-17
SI3167065T1 (sl) 2020-09-30
JP2017520261A (ja) 2017-07-27
HRP20200996T1 (hr) 2021-01-08
CN106661588B (zh) 2020-11-06
US10329571B2 (en) 2019-06-25
WO2016005931A1 (en) 2016-01-14
PH12017500047A1 (en) 2017-05-22
US20190309313A1 (en) 2019-10-10
MX2017000332A (es) 2017-07-28
PT3167065T (pt) 2020-07-01
ES2808906T3 (es) 2021-03-02
PL3167065T3 (pl) 2020-11-16
US20170159060A1 (en) 2017-06-08

Similar Documents

Publication Publication Date Title
BR112017000389A2 (pt) sistema de expressão cistrônico duplo e processo de produção de proteínas
LT3559022T (lt) Baltymų pernešimas susilpinto virulentiškumo bakterijų dėka
EA201790378A1 (ru) Заключенное в липосому аффинное лекарственное средство
BR112018010211A2 (pt) formulação farmacêutica aquosa compreendendo anticorpo anti-pd-l1 avelumab
HK1226083A1 (zh) 用於哺乳動物應用的去免疫志賀毒素亞基效應多肽
EA201690314A1 (ru) Анти-garp-белок и его применения
HUE036362T2 (hu) Baktériumtörzseket tartalmazó készítmények
HUE041969T2 (hu) Baktériumtörzseket tartalmazó készítmények
HUE046221T2 (hu) Bakteriális törzseket tartalmazó készítmények
PE20170665A1 (es) Anticuerpos anti-tau humanizados
BR112017023374A2 (pt) formulação de anticorpo anti-cgrp
CL2013001124A1 (es) Anticuerpo aislado o una proteína que comprende una porción de enlace de antígeno de un anticuerpo dirigido contra un polipéptido de cd40; composicion farmacéutica que comprende dicho anticuerpo; ácido nucleico que codifica el anticuerpo; vector de clonación; proceso de producción del anticuerpo.
EP3003062C0 (en) PRODUCTION OF DRIED VEGETABLE PROTEIN PRODUCTS WITH REDUCED ASTRINGENCY
BR112015004467A2 (pt) método para controlar a heterogeneidade de proteínas
GB2537077A (en) Methods for sequencing nucleic acids
BR112016025792A2 (pt) meios e processos para tratamento de cmv
BR112018012304A2 (pt) composições e métodos para diminuir expressão de tau
SI3652491T1 (sl) Postopek liofiliziranja izdelka
IL250646A0 (en) A process for conjugating a peptide or protein with a reagent containing a leaving group that includes a peg moiety
CL2018001718A1 (es) Sistema de depuración de dióxido de azufre y proceso para la producción de productos de potasio
MD20150109A2 (ro) Construcţii proteice mitocondriale şi utilizările acestora
GT201800102A (es) Polipéptidos que inhiben cd4ol
BR112018070139A2 (pt) expressão de proteínas em bactérias gram-negativas em que a razão entre o volume periplasmático e o volume citoplasmático é entre 0,5:1 e 10:1
EP3430035A4 (en) PRODUCTION OF PROTEINS IN LABYRINE THULOMYCETES
FI20145305A (fi) Proteiinituotteet ja menetelmät niiden valmistamiseksi

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements